Fact-checked by Grok 2 weeks ago

Faropenem

Faropenem is a broad-spectrum oral penem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, demonstrating activity against many Gram-positive and Gram-negative aerobes, anaerobes, and some beta-lactamase-producing strains.^[1]^[2] As the active metabolite of the prodrug faropenem medoxomil (molecular formula C17H19NO8S), it achieves high oral bioavailability of 70-80%, enabling effective treatment of community-acquired infections without intravenous administration.^[2]^[1] Approved in Japan since 1997 and in India since 2010, faropenem is indicated for upper and lower respiratory tract infections (including community-acquired pneumonia and sinusitis), urinary tract infections, skin and soft tissue infections, and gynecological infections, with dosing typically at 200-300 mg three times daily for adults.^[1]^[3] It is not approved by the U.S. FDA and is reserved in Japan for specific cases like extended-spectrum beta-lactamase (ESBL)-producing infections due to concerns over resistance development.^[1] Pharmacokinetically, faropenem exhibits good tissue penetration into sites such as the respiratory tract and urinary system, with a half-life of about 1 hour and primarily renal excretion.^[1] Safety data from clinical studies indicate it is generally well-tolerated, with the most common adverse effect being mild to moderate diarrhea (incidence 5-12%), and it shows a favorable profile particularly in pediatric populations.^[1]^[4] Limited randomized controlled trials support its efficacy, particularly for uncomplicated urinary tract infections and respiratory infections, though further research is needed on resistance patterns and cross-resistance to carbapenems.^[1]

Medical Use

Indications

Faropenem exhibits broad-spectrum antibacterial activity against Gram-positive bacteria such as Streptococcus pneumoniae and Staphylococcus aureus, Gram-negative bacteria including Haemophilus influenzae and Escherichia coli, and anaerobic bacteria like Bacteroides fragilis.^[5]^[6]^[7] In Japan and India, faropenem is approved for the treatment of community-acquired pneumonia, acute bacterial sinusitis, acute exacerbations of chronic bronchitis, uncomplicated skin and skin structure infections, urinary tract infections, and gynecological infections.^[1]^[8]^[9] Emerging and off-label applications include the management of odontogenic infections and multi-drug resistant infections, particularly where oral beta-lactam alternatives are preferred to intravenous administration; it is approved for pediatric respiratory tract infections in regions where available.^[4]^[10] Clinical trials conducted in Japan and India since 2000 have demonstrated efficacy rates of 80-95% for respiratory infections, with pediatric studies reporting clinical response rates of 91% for respiratory tract infections overall, including 85.7% for bronchitis.^[1]^[10] Faropenem's superior oral bioavailability of 72-84% enables outpatient treatment of infections that often require intravenous carbapenems, facilitating broader ambulatory use compared to parenteral options.^[10]^[11]

Dosage and Administration

Faropenem is administered orally, available as film-coated tablets or dry syrup for reconstitution into an oral suspension. The standard adult dosage is 200 mg three times daily for most infections, with treatment duration typically ranging from 5 to 14 days depending on the infection site, such as 7 days for urinary tract infections and 10 to 14 days for pneumonia.^[1]^[7] For pediatric patients over 3 months of age, the recommended dosage is 15 mg/kg/day divided into three doses, not exceeding 600 mg/day.^[4] Faropenem can be taken with or without food.^[4] In patients with renal impairment, dosage reduction or interval prolongation is advised due to prolonged half-life and increased plasma concentrations; no adjustment is required for mild hepatic impairment.^[9]^[12] Clinical response should be monitored within 48 to 72 hours, and the full course must be completed to minimize resistance development.^[7] Dosing follows regulatory guidelines in Japan and India, where it is approved, but it is not authorized in regions like the United States.^[1]^[7]

Adverse Effects

Faropenem is generally well-tolerated, with a favorable safety profile similar to other β-lactam antibiotics. The most common adverse effects are gastrointestinal (GI) in nature, primarily mild to moderate diarrhea resulting from disruption of gut flora. In post-marketing surveillance conducted in Japan from 1997 to 2000 involving over 17,000 patients, the overall incidence of adverse events was 2.96%, with GI disorders accounting for 2.38% (primarily diarrhea at 2.1%). Clinical trials report higher rates in specific populations; for example, diarrhea occurred in 5.8% of pediatric patients across multiple studies and up to 12.4% in adults with uncomplicated urinary tract infections. Other common GI effects include nausea, vomiting, and abdominal pain, though these are less frequent, with incidences typically under 5% in reviewed trials.^[13]^[1]^[1] Less common adverse effects (1-10% incidence) include dermatologic reactions such as rash (0.24% in post-marketing data) and elevated liver enzymes (e.g., ALT/AST), observed in up to 19% of patients in a randomized trial for pulmonary tuberculosis. Headache and taste disturbances have been reported anecdotally in clinical use but lack robust incidence data from large-scale studies. These effects are usually self-limiting and resolve upon discontinuation.^[13]^[14]^[10] Serious adverse effects are rare (<1%) and include anaphylaxis in patients with known β-lactam hypersensitivity, Clostridium difficile-associated diarrhea as a potential complication of broad-spectrum antibiotic use, seizures (particularly in high doses or renal impairment, though less common than with carbapenems), and hematologic changes such as thrombocytopenia or leukopenia (4.55% in the tuberculosis trial). Post-marketing data indicate no severe events leading to death, with most cases resolving after drug withdrawal.^[3]^[1]^[14] Management of adverse effects focuses on symptomatic relief; for GI issues, probiotics or antidiarrheal agents may be used alongside hydration, while severe allergic reactions necessitate immediate discontinuation and supportive care such as antihistamines or epinephrine. Liver function tests should be monitored during prolonged therapy, especially in patients with hepatic risk factors. Long-term use or overuse of faropenem contributes to the broader risk of antibiotic resistance development, particularly among Enterobacterales, as evidenced by increasing resistance patterns in surveillance studies.^[10]^[3]^[1]

Pharmacology

Mechanism of Action

Faropenem is a beta-lactam antibiotic belonging to the penem subclass, which exerts its antibacterial effects by binding irreversibly to penicillin-binding proteins (PBPs) 1 through 3 located on the bacterial cell membrane.^[4] This binding mimics the D-alanine-D-alanine terminus of peptidoglycan precursors, covalently attaching to the active-site serine residue of these PBPs and inactivating their transpeptidase activity.^[4] As a result, faropenem prevents the cross-linking of peptidoglycan chains essential for bacterial cell wall integrity during synthesis, leading to weakened cell walls, osmotic instability, bacterial lysis, and ultimately bactericidal cell death.^[2] This time-dependent killing is observed in vitro against a range of pathogens, with rapid cytolysis demonstrated in models such as Mycobacterium tuberculosis.^[4]^[15] Faropenem demonstrates high affinity for key PBPs in clinically relevant bacteria, including PBP1A, PBP1B, PBP2B, and PBP3 in Streptococcus pneumoniae, though it shows lower affinity for PBP2X.^[16] In Haemophilus influenzae, it effectively targets PBP3, contributing to activity against beta-lactamase-producing strains, while in anaerobes like Bacteroides fragilis, it inhibits multiple PBPs to disrupt cell wall formation.^[16]^[4] These interactions underpin its broad-spectrum efficacy, with MIC90 values typically ≤1 μg/mL for many susceptible pathogens, including Streptococcus species, Haemophilus influenzae, and various anaerobes.^[16] Regarding resistance, faropenem's penem structure confers activity against many beta-lactamase-producing strains, but it is susceptible to hydrolysis by certain extended-spectrum beta-lactamases (ESBLs) such as those of the CTX-M type, as well as carbapenemases, including the class A enzyme KPC-2 (with measurable hydrolysis kinetics) and metallo-beta-lactamases such as VIM-2, NDM-1, and L1, which can significantly reduce its effectiveness against producing strains.^[4]^[17] Faropenem exhibits a significant post-antibiotic effect against certain pathogens, such as Staphylococcus aureus, Streptococcus pneumoniae, and Escherichia coli.^[4]

Pharmacokinetics

Faropenem is typically administered orally as the medoxomil ester prodrug to enhance absorption, achieving a bioavailability of 70-90% in humans.^[1] Peak plasma concentrations (Cmax) of 5-10 μg/mL are reached 1-2 hours (Tmax) after dosing, with absorption unaffected by food.^[4] The volume of distribution (Vd) for faropenem is approximately 20-30 L in healthy adults, indicating moderate distribution into body tissues.^[3] It demonstrates good penetration into key sites of infection, including respiratory secretions, urine, and skin structures, where concentrations can reach 2-5 times those in plasma, supporting its use in infections at these locations.^[1] Faropenem medoxomil is rapidly hydrolyzed by plasma and tissue esterases to the active faropenem form, with no significant hepatic metabolism observed.^[1] Protein binding is concentration-dependent, approximately 90% at therapeutic concentrations (e.g., 5 μg/mL), with saturable binding to albumin.^[18] Excretion of faropenem occurs primarily via the renal route, with 80-90% recovered unchanged in urine through a combination of glomerular filtration and active tubular secretion.^[1] The elimination half-life is 1-2 hours in healthy adults, necessitating multiple daily dosing to maintain therapeutic levels.^[1] In patients with renal impairment, the half-life is prolonged due to reduced clearance, and dose adjustment may be needed; specific data on removal by dialysis are not available. Coadministration with probenecid inhibits tubular secretion, extending drug exposure.^[19]

Chemistry

Structure and Properties

Faropenem belongs to the penem class of beta-lactam antibiotics, representing a structural hybrid between penicillins and cephalosporins, characterized by a beta-lactam ring fused to a five-membered thiazoline ring, with a chiral tetrahydrofuran substituent at the C-2 position.^[20]^[21] This core architecture distinguishes penems from other beta-lactams and contributes to their broad-spectrum activity. The molecular formula of faropenem sodium, the primary pharmaceutical form, is C12H14NNaO5S, with a molecular weight of 307.30 g/mol.^[20] It appears as a white to light brown crystalline powder.^[22] Faropenem sodium exhibits good solubility in water, at least 20 mg/mL, though its stability is pH-dependent, with optimal conditions in neutral to slightly alkaline environments.^[22] Faropenem demonstrates chemical stability against certain beta-lactamases, including the class A enzymes TEM-1 and SHV-1, owing to the stereochemistry of the tetrahydrofuran group at the C-2 position, which hinders enzymatic hydrolysis.^[23]^[24] However, it remains sensitive to hydrolysis by other beta-lactamases. Its pKa value for the strongest acidic group is approximately 3.97, influencing its ionization and solubility profile.^[25] The synthesis of faropenem involves ring expansion of the penicillin nucleus to form the penem core, a method developed by Daiichi Sankyo in the 1980s through key patents on penem derivatives.^[26]^[27] This oral penem's unique bioavailability stems from its prodrug ester form, such as faropenem medoxomil, which features an ester linkage stable in the gastrointestinal tract but hydrolyzable in vivo.^[5]

Available Forms

Faropenem is primarily administered orally in its prodrug form, faropenem medoxomil, which is an ester derivative designed to enhance gastrointestinal absorption, while faropenem sodium serves as the active moiety but is also formulated for oral use rather than injection.^[5]^[7] The medoxomil prodrug is rapidly cleaved by plasma esterases following absorption to release the active faropenem, thereby improving oral bioavailability from less than 50% for the parent compound to over 80%.^[28]^[29] Common formulations include 200 mg film-coated tablets for adult use and an oral suspension at a concentration of 50 mg/5 mL, particularly suited for pediatric patients as a dry syrup that is reconstituted prior to administration.^[30] No intravenous formulation of faropenem is commercially available.^[7] Trade names vary by region, including Farom in Japan, generic faropenem in India (such as Farobact and Faronem), and Orfanem in Bangladesh; the proposed name Orapem for the U.S. market was rejected by the FDA.^[31]^[32] These formulations should be stored at room temperature (15–30°C), protected from moisture and direct sunlight, with a typical shelf life of 2–3 years under proper conditions.^[33]^[34] Faropenem is available by prescription only worldwide and is not sold over-the-counter.^[35]

History and Society

Development

Faropenem was discovered by scientists at the Suntory Institute for Biomedical Research in Japan, which later became part of Asubio Pharma under Daiichi Sankyo, as part of efforts to develop orally active penem antibiotics offering broad-spectrum activity similar to carbapenems but suitable for oral administration.^[31] The compound emerged from research aimed at creating beta-lactam agents resistant to hydrolysis by beta-lactamases, addressing limitations of earlier parenteral-only options in the class.^[29] Key milestones in its development included the initial synthesis and preclinical evaluation during the late 1980s and 1990s, where studies demonstrated faropenem's potent in vitro and in vivo activity against a wide range of Gram-positive, Gram-negative, and anaerobic bacteria, including beta-lactamase producers.^[24] Phase I safety trials in healthy volunteers were conducted in Japan in the mid-1990s, followed by Phase II and III efficacy studies focused on respiratory tract infections, culminating in the approval of faropenem sodium for marketing in Japan in 1997 as the first oral penem antibiotic.^[36] Clinical development faced challenges, including early concerns over potential resistance emergence due to its structural similarity to carbapenems, prompting careful monitoring of susceptibility patterns in preclinical models.^[8] A major focus was optimizing the prodrug faropenem medoxomil, an ester derivative that enhances oral bioavailability from 20-30% for the parent compound to approximately 70-80%, enabling effective gastrointestinal absorption while maintaining stability against hydrolysis.^[1] This prodrug innovation was critical for positioning faropenem as a viable oral alternative to intravenous beta-lactams. In the early 2000s, Daiichi Asubio Pharma partnered with Replidyne for further development outside Japan, with Replidyne sublicensing U.S. rights to Forest Laboratories in 2006 to advance Phase III trials for indications like acute bacterial sinusitis and community-acquired pneumonia.^[31] Core intellectual property included Japanese Patent No. H07-165700 (1995) covering the medoxomil ester prodrug, which provided exclusivity until around 2015 in Japan. These efforts underscored faropenem's role in expanding oral beta-lactam options amid rising antimicrobial resistance pressures.

Regulatory Status and Availability

Faropenem was first approved in Japan in 1997 by the Pharmaceuticals and Medical Devices Agency (PMDA) under the brand name Farom for the treatment of various bacterial infections, including respiratory tract, urinary tract, skin, and gynecological infections. In India, the Central Drugs Standard Control Organisation (CDSCO) authorized faropenem sodium tablets in 2005, followed by approval for oral suspension in 2010, enabling widespread generic production and use for similar indications. Bangladesh's Directorate General of Drug Administration (DGDA) approved faropenem in 2005 as Orfanem tablets, primarily for community-acquired infections. Limited approvals exist in other Asian countries, such as Thailand where prescribing information supports its use for respiratory and urinary tract infections, and the Philippines where it is supplied for similar purposes through regional distribution networks.^[37]^[38] In the United States, the Food and Drug Administration (FDA) received a New Drug Application (NDA) for faropenem medoxomil in December 2005 from Replidyne, targeting acute exacerbations of chronic bronchitis, community-acquired pneumonia, sinusitis, and uncomplicated skin infections. The FDA issued a non-approvable letter in October 2006 citing insufficient efficacy data, followed by another rejection in 2007 requiring additional superiority trials. Efforts halted after Replidyne discontinued late-stage trials in 2008 to conserve resources and filed for bankruptcy in 2009, leaving faropenem investigational only with no marketing approval as of 2025.^[31]^[39]^[40] The European Medicines Agency (EMA) has not approved faropenem for marketing in the European Union, though it may be accessible via special import mechanisms in select member states for compassionate use in resistant infections. The World Health Organization (WHO) classifies faropenem in the AWaRe RESERVE group for monitoring antimicrobial resistance but does not include it on the Model List of Essential Medicines, recommending its use primarily for multidrug-resistant Enterobacterales infections under stewardship guidelines.^[41] Generics dominate the faropenem market in India, accounting for the majority of global supply and sales, with annual consumption reaching approximately 18.9 million standard units by 2014 and continuing to grow; the overall faropenem sodium market was valued at around USD 241 million globally in 2024, driven largely by Asian demand. In Japan, the branded Farom maintains a stable market position for niche applications. Access remains affordable in Asia, with treatment costs estimated at USD 1-2 per day based on standard dosing of 200-300 mg three times daily, though resistance monitoring is emphasized per WHO guidelines to prevent overuse.^[8]^[42]^[43] As of 2025, no new regulatory approvals have been granted globally, though ongoing clinical trials in China, including a randomized controlled study (ChiCTR2000033085) evaluating faropenem for pulmonary tuberculosis and prospective observational research on its safety in pediatric respiratory and urinary tract infections, suggest potential expansion for pediatric indications.^[44]^[45]

References

[1]
A systematic scoping review of faropenem and other oral penems
Dec 22, 2022 · Limited evidence described faropenem to treat infectious disease; only four randomized clinical trials were identified. Faropenem dosing ...
[2]
Faropenem Medoxomil | C17H19NO8S | CID 6918218 - PubChem
Faropenem medoxomil is a broad-spectrum antibiotic that is highly resistant to beta-lactamase degradation. It is being developed jointly by Replidyne, Inc. and ...
[3]
Recent Developments in Penem Antibiotics: Structural and ...
May 11, 2025 · In Japan and India, faropenem is used to treat urinary tract infections (UTIs), respiratory tract infections, skin and soft structure infections ...
[4]
Role of Faropenem in Treatment of Pediatric Infections - NIH
Apr 25, 2022 · Faropenem oral dry syrup is available for the treatment of a wide range of pediatric infections, including upper respiratory tract infections, urinary tract ...
[5]
Faropenem medoxomil: Uses, Interactions, Mechanism of Action
Nov 18, 2007 · Faropenem has demonstrated excellent in vitro activity against common respiratory pathogens, many aerobic gram-positive organisms, and anaerobes ...
[6]
Faropenem, a new oral penem: antibacterial activity against ...
Faropenem was highly active against all the anaerobes tested (MIC90 ≤ 0.5 mg/L) and was bactericidal against both β-lactamase-positive and -negative anaerobes, ...
[7]
Faropenem | Johns Hopkins ABX Guide
### Summary of Faropenem from Johns Hopkins ABX Guide
[8]
Faropenem Consumption is Increasing in India - Oxford Academic
Feb 7, 2016 · In India, faropenem is approved for the treatment of respiratory tract, urinary tract, skin, soft-tissue, and gynecological infections [4]. It ...
[9]
Farobact 300 ER Tablets: Dosage, Uses, Contraindications ...
Faropenem is approved for use in the treatment of upper and lower respiratory tract infections, ear, nose and throat (ENT) infections, genito-urinary ...
[10]
Role of Faropenem in Treatment of Pediatric Infections: The Current ...
Apr 25, 2022 · Excellent clinical responses were reported, with an overall efficacy rate of 93.3%. The overall bacteriological eradication rate of faropenem ...<|separator|>
[11]
Faropenem, a stable and orally bioavailable β-lactam, to counteract ...
May 29, 2023 · Faropenem is an orally administered penem antibiotic which demonstrates broad-spectrum antimicrobial activity against many Gram-positive and ...
[12]
Faropenem | Johns Hopkins ABX Guide
Oct 15, 2022 · Faropenem is currently available as a faropenem sodium salt in several countries in Asia, licensed in Japan since 2007. · The only oral penem.
[13]
Faropenem - Indications, Dosage, Side Effects and Precautions
Faropenem is an antibiotic used for the treatment of upper and lower respiratory infections, urinary tract and gynecological infections, and skin infections.
[14]
[PDF] Faropenem の市販後調査成績
サントリー㈱で開発された faropenem（FRPM）は，各種. ペニシリン結合蛋白への親和性が高く1，2），β–ラクタマーゼ. に対して安定であり3，4），グラム陽性菌・陰性菌に対し広範.
[15]
Randomized control study of the use of faropenem for treating ...
Previous studies demonstrated that oral faropenem for upper respiratory tract infections and urinary tract infections was safe and well tolerated. Almost ...
[16]
Rapid Cytolysis of Mycobacterium tuberculosis by Faropenem ... - NIH
Faropenem is an orally bioavailable (72 to 84% bioavailability) penem antibiotic that is more resistant to hydrolysis by β-lactamases than cephalosporins and ...
[17]
Binding of Faropenem and Other β-Lactam Agents to Penicillin ... - NIH
Faropenem is an oral penem with excellent activity against the primary bacterial pathogens responsible for community-acquired respiratory tract infections, ...
[18]
Faropenem reacts with serine and metallo-β-lactamases to ... - NIH
Feb 9, 2021 · Faropenem is an orally active penem antibiotic with a tetrahydrofuran (THF) C-2 side chain; it is used extensively in Asia to treat respiratory ...<|control11|><|separator|>
[19]
Pharmacokinetic-Pharmacodynamic Assessment of Faropenem in a ...
Faropenem is a β-lactam in the penem subclass that is being developed as an oral prodrug, faropenem medoxomil, for the treatment of respiratory tract infections ...Missing: mechanism | Show results with:mechanism
[20]
Pharmacokinetics of Faropenem - ChemicalBook
In more than ten years' clinical experience of faropenem sodium, no drug interactions have been reported. Possible drug interactions with faropenem ...
[21]
Faropenem sodium | C12H14NNaO5S | CID 23663972 - PubChem
Molecular Formula. C12H14NNaO5S. Synonyms. Faropenem sodium; 122547-49-3; Furopenem; Farom; Fropenum sodium. View More... Molecular Weight. 307.30 g/mol.
[22]
Faropenem - an overview | ScienceDirect Topics
Faropenem is well absorbed by mouth, and is active against a wide range of Gram-positive and Gram-negative pathogens.
[23]
Faropenem sodium | 122547-49-3 - ChemicalBook
Chemical Name: Faropenem sodium ; CBNumber: CB8429283 ; Molecular Formula: C12H14NO5S.Na ; Molecular Weight: 307.3 ; MDL Number: MFCD07357271.
[24]
The in-vitro activity of faropenem, a novel oral penem - PubMed
... beta-lactamase producers were similar to those of non-producers. In hydrolysis studies, faropenem was shown to be highly stable to a number of beta-lactamases ...Missing: pKa | Show results with:pKa
[25]
Faropenem: review of a new oral penem - PubMed
Faropenem demonstrates broad-spectrum in vitro antimicrobial activity against many Gram-positive and -negative aerobes and anaerobes, and is resistant to ...
[26]
Faropenem: Uses, Interactions, Mechanism of Action - DrugBank
Oct 20, 2016 · pKa (Strongest Acidic), 3.97, Chemaxon. pKa (Strongest Basic), -2.8, Chemaxon. Physiological Charge, -1, Chemaxon. Hydrogen Acceptor Count, 5 ...
[27]
US4997829A - Penem compounds, and use thereof - Google Patents
Assigned to DAIICHI SUNTORY PHARMA CO., LTD. ASSIGNMENT OF ASSIGNORS ... The first process is that of obtaining a thiocarboxylic acid ester of the ...
[28]
FAROPENEM | New Drug Approvals
Oct 21, 2021 · Faropenem is an orally active beta-lactam antibiotic belonging to the penem group. [1] It is resistant to some forms of extended-spectrum beta-lactamase.History · Patent · Publication Numberpriority...
[29]
A systematic scoping review of faropenem and other oral penems
Dec 22, 2022 · This scoping review investigated the impact of faropenem and other oral penems on Enterobacterales infection treatment and evaluated evidence for faropenem ...Missing: odontogenic | Show results with:odontogenic
[30]
Recent Developments in Penem Antibiotics: Structural and ... - MDPI
The new antibiotic exhibited broad-spectrum antibacterial activity and was effective against Gram-positive and Gram-negative, anaerobic, and resistant bacteria.2. Penems Used In Therapy · 2.2. Faropenem · 3. Penems Under Development<|control11|><|separator|>
[31]
Faropenem Sodium for Syrup 50mg/5ml - Unibyte Kids
Faropenem Sodium for Syrup 50mg/5ml is an effective suspension manufactured by Unibyte Kids to treat infections. For more information contact us!Missing: concentration | Show results with:concentration
[32]
Faropenem medoxomil: A0026, BAY 56-6854, BAY 566854 ...
The proposed commercial name for faropenem medoxomil, Orapemtrade mark, was not approved by the FDA due to its similarity to another commercially approved drug.Missing: trade | Show results with:trade
[33]
Faropenem | List of Available Brand Names with Prices in Bangladesh
Faropenem: List of Available Brand Names with Prices in Bangladesh ... Beximco Pharmaceuticals Ltd. Unit Price: ৳ 95.00 (5 x 4: ৳ 1,900.00). Tablet Orfanem Tablet.
[34]
Faropenem 200 mg Tablets Manufacutrer / Supplier and Franchise
Store between 15°C and 30°C (59°F and 86°F) temperature. Keep the medication in original containers; Away from direct sunlight; Store in a Cool Place; Store in ...Missing: shelf life
[35]
Faropenem Tablets 200mg - Effective Antibiotic at Best Price
Discover Faropenem Tablets 200mg for treating bacterial infections affecting respiratory and urinary tracts. Available with a shelf life of 24 months and ...
[36]
Farobact 300 Mg Tablet ER | Faropenem - Cheap Medicine Shop
Leading online drugstores, pharmacy stores, and medical supply stores will have Cynomycin but you can buy it on doctor's prescription only.
[37]
[PDF] REFERENCE DATA - Daiichi Sankyo
Nov 7, 2005 · First half year results for the fiscal year ending March 31, 2006 ... Registration preparation. ・Faropenem medoxomil is a prodrug of Faropenem ...
[38]
P1460 – P1884 - PMC - PubMed Central - NIH
... faropenem on penicillin-resistant Streptococcus pneumoniae and beta-lactamase-producing Haemophilus influenzae ... carbapenem resistance is rarely ...
[39]
Faropenem - Wikipedia
Faropenem is an orally active beta-lactam antibiotic belonging to the penem group. It is resistant to some forms of extended-spectrum beta-lactamase.
[40]
Faropenem: Uses, Dosage, Side Effects and More | MIMS Thailand
This information is not country-specific. Please refer to the Thailand prescribing information. Adult: As faropenem medoxomil: 300 mg bid for 7-10 days.
[41]
Faropenem | ZHEJIANG HISOAR PHARMACEUTICAL CO.,LTD.
International Approvals/Standards; Quality Service. Supplied from. China ... South East Asia (e.g. Thailand, Philippines, Singapore). Show more Show less ...
[42]
FDA Issues Non-Approvable Letter For Replidyne, Inc.'s Faropenem
Oct 23, 2006 · The US Food and Drug Administration (FDA) has issued a non- approvable letter for Replidyne's new drug application (NDA) for faropenem medoxomil, a novel oral, ...Missing: bankruptcy | Show results with:bankruptcy
[43]
Replidyne stops faropenem trial to conserve cash - Reuters
Apr 23, 2008 · April 23 (Reuters) - Replidyne Inc said it has discontinued enrollment in a late-stage trial of its antibiotic faropenem to conserve cash.Missing: 2005 2010 bankruptcy
[44]
eEML - Electronic Essential Medicines List
Faropenem. Not recommended as an essential medicine. Listed in AWaRe for monitoring purposes. Not recommended as an essential medicine. MONITORING. ATC codes.
[45]
Faropenem Sodium Market Size & Share 2025-2032
The Faropenem Sodium Market size was estimated at USD 241.44 million in 2024 and expected to reach USD 258.60 million in 2025 ...
[46]
Faronem 200 Tablet: Uses, Side-effects, Price, Dosage & More Info
Mar 17, 2025 · Offer Price, ₹476.30 ; You Save, ₹142.27 (23% on MRP) ; Contains, Faropenem(200.0 Mg) ; Uses, Bacterial infections ; Side effects, Diarrhoea, nausea ...Missing: Asia | Show results with:Asia
[47]
Randomized Control Study of the Use of Faropenem for Treating ...
Sep 18, 2025 · Conclusions: Our study proved oral faropenem regimen can be used for the treatment of tuberculosis with fewer adverse events. (Chinese Clinical ...
[48]
Safety and Efficacy of Faropenem in Respiratory - and Urinary Tract ...
Several studies have demonstrated the efficacy of faropenem in various clinical settings. Milatovic et al. [5] reported substantial in vitro activity of ...